![]() |
市場調查報告書
商品編碼
1284226
到 2028 年的麻醉設備市場預測——按產品、應用、最終用戶和地區進行的全球分析Anesthesia Devices Market Forecasts to 2028 - Global Analysis By Product, Application, End User and By Geography |
根據Stratistics MRC,2022年全球麻醉設備市場規模將達到177.7億美元,2028年將達到346.4億美元,預測期內復合年增長率為11.77%。預計將達到美元。
在手術過程中,麻醉機用於控制呼吸、血壓、血流、心率和節律。 麻醉引起的醫療狀況包括鎮痛、麻痺、健忘症和意識喪失,患者失去感覺和意識。 為了給戴著氧氣面罩的患者輸送氣體,這些機器會輸送可變的混合氣體,然後將這些混合氣體泵入呼吸系統。 麻醉機控制輸送給患者的氣體混合物,包括氧氣、一氧化二氮和其他氣體。
根據 PubMed Central 於 2022 年 7 月發表的一篇論文,進行的研究開發了一種智能模型,可以幫助根據單通道 EEG 信號預測麻醉深度。 因此,這些新技術的開發也有望促進市場的增長。
對市場增長產生重大影響的一個因素是越來越多的老年人容易患慢性病。 例如,根據 2022 年 8 月發布的英國心臟基金會概況,估計英國有 760 萬人患有心髒病或循環系統疾病。 報告稱,在英國,超過一半的人在他們生命中的某個階段曾患過心髒病或循環系統疾病,而同時患有合併症的人數幾乎是這一數字的兩倍。 越來越多的需要麻醉的手術、慢性病的流行和老年人口的增加是推動市場增長的主要因素。
阻礙市場擴張的主要因素之一是廠商之間的激烈競爭。 全球麻醉機市場競爭激烈,國內外廠商紛紛湧入。 產品種類繁多的領先製造商擁有必要的技術、資金、營銷資源、強大的區域影響力和大量的研發支出。 另一方面,中小供應商的產品線有限,資金和技術資源也有限。 因此,這些因素將在預測期內抑制全球市場的增長。
預計麻醉監測技術的不斷進步也將推動市場擴張。 例如,根據 PubMed Central 於 2022 年 7 月發表的一篇論文,進行了一項研究,其中創建了一個智能模型來幫助預測單通道 EEG 信號的麻醉深度。 因此,此類新技術的開發也有望加速市場的擴張。
在預測期內限制全球麻醉市場增長的主要因素之一是導致嚴重傷害和死亡的產品召回數量不斷增加。 例如,AMSORB PLUS PREFILLED G-CAN 1.0L 於 2021 年 9 月被醫院設備製造商 Armstrong Medical Limited 召回,原因是麻醉期間患者氣體流量減少。 根據 FDA 的說法,這是一級召回,是最嚴重的召回類別。 使用這些設備可能會導致死亡或重傷。 由於流量問題,麻醉機的使用前或“CHECK-OUT”測試可能會失敗。 這些嚴重的問題限制了市場的增長。
COVID-19 疫情已經擴大到最初在中國爆發的範圍之外,世界衛生組織 (WHO) 已宣布進入大流行狀態。 受疫情影響,醫院活動銳減。 由於大流行早期 COVID-19 病例激增,世界各地的所有醫院都取消了所有計劃和擇期手術。 大流行導致患者監測和慢性病管理受到嚴重干擾,許多患者無法到達醫院,手術也被推遲。 不必要手術的減少是市場擴張的推動力。 此外,麻醉設備市場也受到麻醉設備也用於 COVID-19 患者通氣這一事實的積極影響。
2020 年,骨科行業預計將主導市場,並在預測期內保持主導地位。 這是由於骨科疾病的發病率和患病率不斷增加,老年人口不斷增加,公眾對骨科手術需求的認識不斷提高,以及技術的不斷進步推動了骨科手術的增長。並被認為支持增長麻醉設備市場。
在預測期內,送貨機領域的市場份額擴張顯著。 在麻醉輸送機的幫助下,在保持通氣的同時向患者連續或間歇施用麻醉劑。 移動式麻醉機和固定式麻醉機都是麻醉輸送系統的類型。 安裝在天花板上並帶有一個或多個鉸接臂,麻醉機可以輕鬆移動到不同位置,而不會因電纜和管道弄亂地板。 預計這些優勢將在預測期內增加對獨立麻醉機的需求。
由於肥胖、心血管疾病和各種癌症等疾病的激增導致開放和微創手術的增加,預計在整個預測期內北美將佔據全球市場的很大一部分。 此外,由於慢性病微創手術的增加,該地區的麻醉設備市場正在擴大。 同樣,在 2022 年 11 月,加拿大癌症協會預測當年將有 233,900 人被診斷出患有癌症。 發病率的增加主要是由於加拿大的老齡化和人口膨脹。 因此,在預測期內,癌症患病率上升預計將增加麻醉機的使用,推動該地區的市場增長。
由於患者人數眾多、醫療保健系統不斷擴大、老年人口不斷增加以及手術數量不斷增加,亞太地區正在為市場的利潤豐厚的增長做出貢獻。 由於醫療保險體系的完善、經濟的快速增長、對間歇流量麻醉機的需求增加、肥胖治療和心血管手術等手術率的上升以及癌症患者的增加,中國目前佔據最大的市場份額。我在這裡。 此外,醫療旅行正在增加,利用中國和印度等國家提供的廉價醫療服務,這正在推動該地區的增長。
2022 年 5 月,斐雪派克醫療保健有限公司推出了兩款專為麻醉應用開發的新產品。 經過數年的研發,公司已面向部分市場推出了 Optiflow Switch 和 Optiflow Trace 鼻內高流量接口設備。
2022 年 4 月,Ambu 的 Ambu(R) aScope(TM) Gastro 和 Ambu(R) aBox(TM)2 以及 Ambu 一次性胃鏡在日本獲得了 CE 標誌和市場許可。我們宣布將擴大在歐洲和日本部署下一代顯示生態系統。 胃鏡檢查是一個每年使用可重複使用的內窺鏡系統進行超過 2000 萬例手術的領域,而 Ambu 進入這個市場是為了解決當前可重複使用的內窺鏡的局限性。
2022 年 3 月,B.Brown 收購了專門從事透析濃縮液製備的 Intermedt Medizin & Technik GmbH。 隨著完全整合到 Intermedt Medizin & Technik GmbH 集團,B. Braun 作為體外血液處理(透析)系統供應商完善了 B. Braun Avitum 部門的廣泛產品組合。
According to Stratistics MRC, the Global Anesthesia Devices Market is accounted for $17.77 billion in 2022 and is expected to reach $34.64 billion by 2028 growing at a CAGR of 11.77% during the forecast period. During surgical procedures, anesthesia devices are used to control breathing, blood pressure, blood flow, heart rate, and rhythm. Anesthesia-induced medical conditions, such as analgesia, paralysis, amnesia, or unconsciousness, cause patients to lose feeling or awareness. In order to administer gases to patients wearing oxygen masks, these machines deliver variable gas mixtures, which are then delivered to the breathing systems. Anesthetic machines control the mixture of gases that are given to patients, which includes oxygen, nitrous oxide, and other gases.
According to an article published by PubMed Central in July 2022, a study was conducted where an intelligence model was developed that helped in predicting the depth of anesthesia from a single-channel electroencephalograph (EEG) signal. Thus, the development of such newer technologies is also expected to enhance the market's growth.
A significant factor actively influencing the growth of the studied market is the rising geriatric population, which is susceptible to chronic diseases. For instance, 7.6 million people in the UK are estimated to be affected by heart or circulatory diseases, according to the British Heart Foundation Factsheet, which was published in August 2022. According to the same source, in the United Kingdom, more than half of people will experience a heart or circulatory condition at some point in their lives, and roughly twice as many people are living with these conditions. A rise in the number of surgical procedures requiring anesthesia, an increase in the number of such procedures, the prevalence of chronic diseases, and the rising geriatric population are the main factors promoting the market's growth.
One of the main obstacles preventing market expansion is the fierce competition among vendors. The abundance of local and international vendors makes the market for anesthesia equipment competitive worldwide. A wide range of products are offered by leading suppliers, who also have the necessary technical, financial, and marketing resources, a strong geographic footprint, and significant R&D expenditures. Small and medium-sized suppliers, on the other hand, have constrained financial and technical resources in addition to constrained product offerings. Therefore, during the projected period, these factors will restrain the growth of the global market.
The market's expansion is also anticipated to be aided by the growing number of technological advancements in anesthesia monitoring technology. For instance, a study was conducted where an intelligence model was created to aid in predicting the depth of anesthesia from a single-channel electroencephalograph (EEG) signal, according to an article published by PubMed Central in July 2022. Therefore, it is anticipated that the development of these newer technologies will also accelerate market expansion.
One of the key factors limiting the growth of the global anesthesia market over the forecast period is the rising number of product recalls resulting in serious injuries or fatalities. For instance, AMSORB PLUS PREFILLED G-CAN 1.0L is recalled by hospital equipment manufacturer Armstrong Medical Limited in September 2021 due to the patients' reduced gas flow during anesthesia. This is a Class I recall, the most serious category of recall, according to the FDA. The use of these devices could result in fatalities or severe injuries. The pre-use or "CHECK-OUT" test on the anesthesia machine could fail as a result of the flow issues. Such serious issues limit market growth.
The COVID-19 outbreak has expanded outside of the initial Chinese outbreak, and the World Health Organization (WHO) has declared a pandemic situation. Hospital activities have drastically decreased as a result of the epidemic situation. Due to the rising COVID-19 cases in the early stages of the pandemic, all hospitals worldwide cancelled all planned and elective surgeries. As a result of the pandemic, patient monitoring and chronic disease management were severely disrupted; many patients were unable to visit hospitals, and surgeries were postponed. The decrease in unnecessary surgeries has driven the market's expansion. Additionally, the market for anesthesia devices was positively impacted by the fact that anesthesia devices were also used to ventilate COVID-19 patients.
In 2020, the orthopedics industry dominated the market and is estimated to hold the dominant position throughout the forecast period. This is attributed to an increase in the incidence and prevalence of orthopedic disorders, a growing elderly population, rising public awareness of the need for orthopedic surgery, and ongoing technological advancements that are encouraging an increase in orthopedic surgery, which will support the growth of the anesthesia devices market.
During the anticipated period, the delivery machine segment's market share growth will be significant. The continuous or intermittent administration of an anesthetic agent to a patient while maintaining ventilation is done with the aid of anesthesia delivery machines. Mobile and stationary anesthesia delivery systems are both types of anesthesia delivery systems. The anesthesia machine, which is mounted on the ceiling and has one or more articulated arms, can be easily moved to different locations without littering the floor with cables and tubes. These benefits will cause the demand for self-contained anesthesia machines to increase over the course of the forecast period.
Due to the rapid rise in diseases like obesity, cardiovascular issues, and various cancers, which has led to an increase in the number of open and minimally invasive surgeries, North America is anticipated to account for a sizeable portion of the global market throughout the forecast period. Additionally, the region's anesthesia device market is expanding due to the rise in minimally invasive surgeries for chronic diseases. In a similar vein, the Canadian Cancer Society predicted in November 2022 that 233,900 people would receive a cancer diagnosis that year. The aging and expanding population of Canada is largely to blame for this increase in incidence. Therefore, over the course of the forecast period, the rising incidence of cancer is anticipated to increase the use of anesthesia devices and fuel market growth in this region.
A large patient base, an expanding healthcare system, a growing geriatric population, and an increase in surgeries have all contributed to the market's lucrative growth in the Asia-Pacific region. Owing to its extensive health insurance system, rapid economic growth, rising demand for intermittent flow anesthetic machines, rising rates of surgeries like bariatric and cardiovascular procedures, and rising cancer cases, China currently holds the largest market share. Additionally, a rise in medical travel due to the inexpensive medical care provided by nations like China and India will boost regional growth.
Some of the key players profiled in the Anesthesia Devices Market include 3M Company, Airsep Corporation, Ambu A/S, B. Braun Melsungen AG, Becton Dickinson, CAIRE Inc., Dragerwerk AG & Co. KGaA, Fisher & Paykel Healthcare, GE Healthcare, ICU Medical, Inc., Karl Storz GmbH & Co. KG, Koninklijke Philips N.V., Medtronic PLC, Smiths Group, SunMed, Teleflex Incorporated and Ventlab.
In May 2022, Fisher & Paykel Healthcare Corporation Limited launched two new products developed specifically for use in anesthesia applications. The company released the Optiflow Switch and Optiflow Trace nasal high-flow interface devices into select markets following several years of R&D.
In April 2022, Ambu announces that Ambu® aScope™ Gastro and Ambu® aBox™ 2 have received CE mark and market clearance for Japan, and Ambu will expand the global launch of its single-use gastroscope and next-generation display ecosystem to include Europe and Japan. Gastroscopy is a segment where more than 20 million procedures take place annually with reusable endoscope systems, and Ambu enters this market to address the current limitations of reusable endoscopes.
In March 2022, B. Braun acquires Intermedt Medizin & Technik GmbH, a specialist in the preparation of dialysis concentrates. With the full integration of Intermedt Medizin & Technik GmbH into the Group, B. Braun has completed the extensive product portfolio of its B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).
Note: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa Regions are also represented in the same manner as above.